{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-009248","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.430706+00:00","generated_at":"2026-06-15T04:27:49.903873+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"HOOKIPA Q1 net loss $19.7M; cash $110M; milestones from Roche and Gilead; Phase 2 data on track for Q2 2023","bullets":["Q1 net loss $19.7M vs $18.0M YoY; revenue $3.2M (up from $1.4M) on higher collaboration recognition.","Cash $110.0M at March 31, 2023, down from $113.4M at Dec 31, 2022; used in operations partly offset by collaboration funds.","Achieved $10M milestone from Roche for HB-700 (KRAS-mutated cancers) and $5M from Gilead for HB-400 (chronic hepatitis B).","Phase 2 data for HB-200 in HPV16+ head and neck cancer with pembrolizumab expected in Q2 2023; Phase 1 trials initiated for HB-300 and HB-400.","Appointed Terry Coelho to Board of Directors; preclinical data presented at AACR on arenaviral combo with Roche's PD1-IL2v."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-009248","json":"https://secwatch.observer/filing/0001558370-23-009248.json","markdown":"https://secwatch.observer/filing/0001558370-23-009248.md","text":"https://secwatch.observer/filing/0001558370-23-009248.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000155837023009248/0001558370-23-009248-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000155837023009248/hook-20230511x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:27:49.903873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2cafa4bf0398bbcb73f70861128625a0e66f0d8c","claim":"HOOKIPA Pharma Inc. reported First Quarter 2023 results: revenue $3.2 million, net income $19.7 million.","evidence_excerpt":"Revenue was $3.2 million for the three months ended March 31, 2023 compared to $1.4 million for the three months ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760542/000155837023009248/0001558370-23-009248-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First Quarter 2023"},{"label":"Revenue","value":"$3.2 million"},{"label":"Net income","value":"$19.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}